Stockscreener 앱 받기
1.17
3.31%
-0.04
시장 영업 전:
1.21
0.04
+3.42%
Vivosim Labs Inc 주식(VIVS)의 최신 뉴스
VIVS Q3 2025 Earnings: EPS Surprise Beats Estimates, Revenue UnreportedEstimate Dispersion - newsline.com
VivoSim Labs Faces Pressure: VIVS Stock Falls Over 10% as Key Support ApproachesIchimoku TK Cross - newsline.com
VIVS Q3 2025 Earnings: EPS Surprise of 10.83% Beats Estimates Amid Pre-Revenue PhaseEPS Surprise History - newsline.com
VIVS Q3 2025 Earnings: EPS Surprises to the Upside Amid Operational FocusPretax Income Report - The Legal Advocate
VIVS Q3 2025 Earnings: Narrower-Than-Expected Loss Drives Stock HigherAnnual Earnings Summary - thelegaladvocate.com
VIVS Q3 2025 Earnings: Narrower-Than-Expected Loss Drives Positive Stock ReactionNet Profit Margin - newsline.com
VIVS Q3 2025 Earnings: EPS Beat on Cost Management Amidst Ongoing DevelopmentEarnings Analysis - The Legal Advocate
VivoSim Labs (VIVS) Dips Slightly as Stock Tests Key Support LevelsRounding Bottom - The Legal Advocate
VivoSim Labs (VIVS) News Flow - Moomoo
VivoSim Labs Inc. (VIVS) Edges Up 1.49% as It Tests Resistance at $1.43MESA MA - The Legal Advocate
VIVS Q3 2025 Earnings: EPS Surprise Beats Estimates Amid Unreported RevenueSocial Signal Watchlist - Newser
VIVS Stock Chart | VIVOSIM LABS INC (NASDAQ:VIVS) - ChartMill
VIVS Q4'25 Earnings: EPS estimate is (2.04) USD - TradingView
VIVS Stock Price, Quote & Chart | VIVOSIM LABS INC (NASDAQ:VIVS) - ChartMill
Number of shareholders of VivoSim Labs, Inc. – NASDAQ:VIVS - TradingView
Lobbying Update: $10,000 of VIVOSIM LABS INC. lobbying was just disclosed - Quiver Quantitative
VivoSim Labs, Inc. (VIVS) Eps Diluted (TTM) - Zacks Investment Research
What VivoSim Labs (VIVS) capital allocation tells us | Q3 2025: Better Than ExpectedGuidance Update - newser.com
VivoSim Platform Predicts Gastrointestinal Toxicity - GlobeNewswire
VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing - GlobeNewswire
VIVS Price Today: VivoSim Labs, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
VIVS VivoSim Labs notches 32.1 percent Q3 2025 revenue growth, shares edge higher on narrower than expected loss.AI Stock Signals - Newser
VivoSim Labs (VIVS) Stock: Is It a Compelling Buy (-4.35%) 2026-04-20Earnings Beat Stocks - Cổng thông tin điện tử Tỉnh Sơn La
VIVS Technical Analysis & ETF Price Forecast - Intellectia AI
Gap Down: Will VivoSim Labs Inc benefit from AI trendsEarnings Trend Report & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Esousa Group reports 9.9% stake in VivoSim Labs (NASDAQ: VIVS) - Stock Titan
VIVS SEC FilingsVivoSim Labs Inc 10-K, 10-Q, 8-K Forms - Stock Titan
VivoSim Labs Announces $4 Million Public Offering to Accelerate Adoption of 3D Human Tissue Models for Drug Testing - Minichart
VivoSim Labs Prices Best-Efforts Public Offering - TipRanks
VivoSim Labs Raises ~$2.5M in Initial Tranche; Signs Purchase and Placement Agreements - TradingView
VivoSim Labs (Nasdaq: VIVS) raises $3M in first tranche of $4M deal - Stock Titan
VivoSim Labs (NASDAQ: VIVS) registers 3.51M shares with detachable warrants - Stock Titan
VIVS Stock Analysis: VivoSim Labs Inc gains 13.68 percent to 1.62 amid bullish momentum - Newser
VivoSim Announces Pricing of up to a $4 Million Public Offering - Sahm
VivoSim Labs prices $4 million public offering at $1.14/share By Investing.com - Investing.com Australia
VivoSim Labs prices $4M public offering at $1.14 per share - Investing.com Australia
VivoSim Labs, Inc. (VIVS) stock price, news, quote and history - au.finance.yahoo.com
[EFFECT] VivoSim Labs, INC. SEC Filing - Stock Titan
VivoSim Labs (NASDAQ: VIVS) outlines $4M two-tranche stock and warrant financing - Stock Titan
Aug Breakouts: Is VivoSim Labs Inc benefiting from innovation trendsWeekly Gains Summary & Long-Term Safe Investment Ideas - baoquankhu1.vn
Published on: 2026-03-29 07:44:35 - baoquankhu1.vn
VivoSim Labs (NASDAQ: VIVS) files S-1 for $4M unit offering - Stock Titan
VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing - GlobeNewswire
VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs - Yahoo Finance
VivoSim Labs, Inc.: Fundamental Analysis and Financial Ratings | 4OR | US68620A3023 - marketscreener.com
Market Catalysts: What is the cash position of VivoSim Labs Inc2026 Price Swings & Reliable Trade Execution Plans - baoquankhu1.vn
Is VivoSim Labs Inc. stock a buy before product launchesJuly 2025 Rallies & Safe Capital Investment Plans - Naître et grandir
Buyback Watch: How much upside does VivoSim Labs Inc haveTrade Analysis Summary & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
Why Is VIVS Stock Up 79% Today? - Stocktwits
VIVS Earnings History & Surprises | EPS & Revenue Results | VIVOSIM LABS INC (NASDAQ:VIVS) - ChartMill
VivoSim names Raghunathan as VP of global sales By Investing.com - Investing.com Canada
1.27%
1.43%
자본화:
|
볼륨(24시간):